Aspiriant LLC’s iShares S&P 100 ETF OEF Stock Holding History

Aspiriant LLC’s Portfolio OEF Stock Details OEF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,568	Closed	-$269K	–	206
2020 Q4	$269K	Sell	1,568 -1,202	-43%	-$196K	0.02%	180
2020 Q3	$431K	Hold	2,770	–	–	0.03%	161
2020 Q2	$395K	Hold	2,770	–	–	0.04%	143
2020 Q1	$329K	Buy	+2,770	New	+$382K	0.03%	149

Other funds holding OEF

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MFW

Meristem Family Wealth Minnetonka, Minnesota $925M AUM 14.15% 1-Year Est. Return

Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return

RVPG

Relative Value Partners Group $772M AUM 15.6% 1-Year Est. Return

Aspiriant LLC's OEF Position: Q1 2021 in Review

Aspiriant LLC sold out of iShares S&P 100 ETF (OEF) in Q1 2021, closing a stake of 1,568 shares — an estimated $269K sold.

Aspiriant LLC first reported a position in OEF in Q1 2020 and held it in 4 quarters. The position peaked at $431K in Q3 2020. 425 funds tracked by Wall St. Rank hold OEF as of Q1 2021.

Aspiriant LLC reported no remaining iShares S&P 100 ETF position as of Q1 2021 after selling out during the quarter.
Aspiriant LLC sold 1,568 iShares S&P 100 ETF shares in Q1 2021, an estimated $269K.
Aspiriant LLC first reported a position in iShares S&P 100 ETF in Q1 2020 and held it in 4 quarters.
Aspiriant LLC's iShares S&P 100 ETF position peaked at $431K in Q3 2020.
425 funds tracked by Wall St. Rank held iShares S&P 100 ETF as of Q1 2021.

Based on Aspiriant LLC's 13F filing for Q1 2021, filed 11 May 2021.